ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Lin, Anqi; Zhang, Hongman; Meng, Hui; Deng, Ze; Gu, Tianqi; Luo, Peng*; Zhang, Jian*南方医科大学
Frontiers in Immunology2021-9-16DOI: 10.3389/fimmu.2021.667875
8被引7阅读
引用收藏
分享

摘要

Translational research on immune checkpoint inhibitors (ICIs) has been underway. However, in the unselected population, only a few patients benefit from ICIs. Therefore, screening predictive markers of ICI efficacy has become the current focus of attention. We collected mutation and clinical data from an ICI-treated non-small cell lung cancer (NSCLC) cohort. Then, a univariate Cox regression model was used to analyze the relationship between tumor necrosis factor alpha signaling mutated (TNF alpha-MT) and the prognosis of immunotherapy for NSCLC. We retrospectively collected 36 NSCLC patients (local-cohort) from the Zhujiang Hospital of Southern Medical University and performed whole-exome sequencing (WES). The expression and mutation data of The Cancer Genome Atlas (TCGA)-NSCLC cohort were used to explore the association between TNF alpha-MT and the immune microenvironment. A local cohort was used to validate the association between TNF alpha-MT and immunogenicity. TNF alpha-MT was associated with significantly prolonged overall survival (OS) in NSCLC patients after receiving immunotherapy. Additionally, TNF alpha-MT is related to high immunogenicity (tumor mutational burden, neoantigen load, and DNA damage response signaling mutations) and enrichment of infiltrating immune cells. These results suggest that TNF alpha-MT may serve as a potential clinical biomarker for NSCLC patients receiving ICIs.

学科与关键词

关键词
TNF alphaNSCLCICIsbiomarkertumor microenvironment
相关
加载中…
  • ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
    Zhang, Jiexia; Zhou, Ningning; Lin, Anqi; Luo, Peng; Chen, Xin; Deng, Huojin; Kang, Shijun; Guo, Linlang*; Zhu, Weiliang*; Zhang, JianCancer Immunology, Immunotherapy, 2021, 70(1): 137-151.被引 60
  • B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
    Lin, Anqi; Fang, Jianbo; Cheng, Quan; Liu, Zaoqu; Luo, Peng*; Zhang, Jian*Journal of Inflammation Research, 2022, 15.
  • Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
    Wen, Yang; Lin, Anqi; Zhu, Weiliang; Wei, Ting; Luo, Peng*; Guo, Linlang*; Zhang, Jian*Frontiers in Pharmacology, 2021, 12: 645862.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2021-09-16
卷期
第 12 卷
页码
667875
DOI
10.3389/fimmu.2021.667875
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province [2018A030313846, 2021A1515012593]; Science and Technology Planning Project of Guangdong Province [2019A030317020]; National Natural Science Foundation of China [81802257, 81871859, 81772457]

作者

  • L

    Lin, Anqi (第一作者)

    southern med univ

  • Z

    Zhang, Hongman

    southern med univ

查看全部 7 位作者收起作者
  • M

    Meng, Hui

    southern med univ

  • D

    Deng, Ze

    southern med univ

  • G

    Gu, Tianqi

    southern med univ

  • L

    Luo, Peng (通讯)

    southern med univ

  • Z

    Zhang, Jian (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417